FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunoglobulin topics
Immunoglobulin
Antibodies
Immunoglobulins
Recombinant
Polypeptide
Nucleic Acid
Cancer Cell
G Proteins
Prophylactic
Metalloprotein
Monoclonal
Cancer Cells
Metastasis
Extracellular
Adhesion Molecule

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunoglobulin patents



      
           
This page is updated frequently with new Immunoglobulin-related patent applications. Subscribe to the Immunoglobulin RSS feed to automatically get the update: related Immunoglobulin RSS feeds. RSS updates for this page: Immunoglobulin RSS RSS


Date/App# patent app List of recent Immunoglobulin-related patents
08/14/14
20140227293
 Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) patent thumbnailMethod for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (igpr-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and prevention of cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (igpr-1) protein or expression which is a soluble extracellular domain igpr-1.
08/14/14
20140227270
 Bispecific anti-cxcr7 immunoglobulin single variable domains patent thumbnailBispecific anti-cxcr7 immunoglobulin single variable domains
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting cxcr7 mediated tumour growth..
08/14/14
20140227267
 Bovine fusion antibodies patent thumbnailBovine fusion antibodies
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the cdr3h.
08/14/14
20140227264
 Drug fusions and conjugates with extended half life patent thumbnailDrug fusions and conjugates with extended half life
The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules.
08/07/14
20140221625
 B cell lineage based immunogen design with humanized animals patent thumbnailB cell lineage based immunogen design with humanized animals
Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in b-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design..
08/07/14
20140221613
 Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g patent thumbnailNovel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein g, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody. The present invention relates to: a protein that is reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a multimer comprising an extracellular domain of wild type one, which is a domain having a binding activity to a protein comprising an fc region of immunoglobulin g, while keeping a high antibody-binding activity in a neutral region, and also has a binding activity to a protein comprising the fc region of immunoglobulin g, wherein the protein comprises a tandem-type multimer of a mutant of the extracellular domain; and others..
08/07/14
20140220562
 Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy patent thumbnailMethod of predicting responsiveness of b cell lineage malignancies to active immunotherapy
Predictive biomarkers identify those patients suffering from immunoglobulin positive (ig+) b lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the cdr1 (herein termed cdr1-y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of cdr1 tyrosine residues (herein termed cdr1-yhi) is predictive of a low anti tumor response..
08/07/14
20140220019
 Dual variable domain immunoglobulins and uses thereof patent thumbnailDual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
08/07/14
20140220017
 Serum half-life extension using igbd patent thumbnailSerum half-life extension using igbd
The present invention relates to complexes comprising (i) an immunoglobulin (ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the ig binding moiety specifically binds to the constant domain 1 of the heavy chain (ch1) of an ig molecule and their use for therapy and prophylaxis.. .
08/07/14
20140220015
 Combinations of modalities for the treatment of diabetes patent thumbnailCombinations of modalities for the treatment of diabetes
A method of treating, preventing, or delaying the progression of type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a t-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic t-lymphocyte-associated antigen 4 (ctla4) molecule and a type 1 diabetes autoantigen.
08/07/14
20140220012
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
08/07/14
20140220009
Compositions and methods for treating cocaine-related disorders
A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a murine lambda light chain variable region, a human gamma heavy chain variable region, and a human kappa or lambda light chain constant region..
08/07/14
20140219912
Dual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
07/31/14
20140213774
Process for obtaining immunoglobulins from colostral milk
(c) the first permeate p1 is subjected to ultrafiltration thus producing a second permeate p2 which contains lactose and minerals, and a second retentate r2, in which the immunoglobulins are concentrated.. .
07/31/14
20140213773
Adam6 mice
Mice are provided that comprise a reduction or deletion of adam6 activity from an endogenous adam6 locus, or that lack an endogenous locus encoding a mouse adam6 protein, wherein the mice comprise a sequence encoding an adam6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic adam6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating.
07/31/14
20140213772
Cross-over dual variable domain immunoglobulin constructs
Engineered cross-over dvd-ig binding proteins that bind to two or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
07/31/14
20140213768
Dual variable domain immunoglobulin and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
07/31/14
20140212440
Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin.
07/31/14
20140212435
Rapid clearance of antigen complexes using novel antibodies
The present invention relates to immunoglobulins that bind ige and fcγriib with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored ige. Such compositions are useful for treating ige-mediated disorders, including allergies and asthma..
07/31/14
20140212416
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long hcdr3s from non-human vertebrates and cells.
07/24/14
20140206019
Fc-function assay
The present invention discloses a method of assaying fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a f-s-l peptide-lipid construct. The f-s-l peptide construct comprises a functional group (f) that is a target antigen for a complement activating immunoglobulin, a spacer group (s) covalently linking f to l and a lipid group (l).
07/24/14
20140205607
Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Antibody vrc01 represents a human immunoglobulin that neutralizes—˜90% of diverse hiv-1 isolates. To understand how such broadly neutralizing hiv-1 antibodies develop and recognize the viral envelope, we used x-ray crystallography and 454 pyrosequencing to characterize additional antibodies from hiv-1-infected individuals.
07/24/14
20140205597
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/24/14
20140205560
Multimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (il-15) polypeptide or a functional fragment thereof.
07/17/14
20140200331
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the ch1 and/or cl domains, amino acid modifications in the vh and/or vl domains or a combination thereof.
07/17/14
20140200159
Identifying antigen clusters for monitoring a global state of an immune system
Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.. .
07/17/14
20140199316
Methods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
07/17/14
20140199295
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/10/14
20140193838
Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g.
07/10/14
20140193407
Drug fusions and conjugates
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and glp and/or exendin molecules.
07/10/14
20140193399
Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen cd3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to cd3.
07/10/14
20140193359
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
07/03/14
20140187753
Hetero-dimeric immunoglobulins
The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.. .
07/03/14
20140186345
Method of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month..
07/03/14
20140186293
Immunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..
06/26/14
20140179898
Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent
A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140179550
Immunoglobulin fc libraries
Methods and composition for the screening and isolation of aglycosylated antibody fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated fc domains that bind to fc receptors or preferentially bind to particular fc receptors are described.
06/26/14
20140179547
Methods for the generation of multispecific and multivalent antibodies
The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a kappa constant domain and the other of a lambda constant domain.
06/26/14
20140178916
Method of neonatal serological diagnosis
The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins g by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life.
06/26/14
20140178869
Detection of immunoglobulin light chain restriction by rna in situ hybridization
The invention provides a method for detecting immunoglobulin light chain restriction and clonality in b cells by obtaining a sample of b cells from a subject; conducting a duplex in situ hybridization assay on the sample using (i) at least one probe set which is designed to specifically hybridize to immunoglobulin kappa chain constant region (igkcr) rna; and (ii) at least one probe set which is designed to specifically hybridize to immunoglobulin lambda chain constant region (iglcr) rna; detecting signal associated with hybridized igkcr probe and signal associated with hybridized iglcr probe in a population of b cells in the sample; and determining a pattern of signal associated with hybridized igkcr probe and hybridized iglcr probe within individual cells in the b cell population, wherein the pattern of signal within individual cells indicates the presence or absence of light chain restriction and clonality of the b cells.. .
06/26/14
20140178390
Biological materials related to cxcr7
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting cxcr7 mediated tumour growth..
06/26/14
20140178364
Compositions and methods for targeting type 1 interferon producing cells
The present disclosure provides a method for treating lupus, sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (il-3rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p dcs) and basophils to which it binds.. .
06/26/14
20140178361
Method for polyclonal immunoglobulin g production by human b cells
This application relates to an in vitro method of producing a polyclonal igg preparation. The method comprises (i) placing a polyclonal b-cell population enriched in igg-secreting b cells in a culture medium; and (ii) culturing the polyclonal b-cell population under conditions enabling the production of the polyclonal igg preparation from the polyclonal b-cell population.
06/26/14
20140178294
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.


Popular terms: [SEARCH]

Immunoglobulin topics: Immunoglobulin, Antibodies, Immunoglobulins, Recombinant, Polypeptide, Nucleic Acid, Cancer Cell, G Proteins, Prophylactic, Metalloprotein, Monoclonal, Cancer Cells, Metastasis, Extracellular, Adhesion Molecule

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunoglobulin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunoglobulin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3438

4041

0 - 1 - 79